Exchange: NYSEArca·Updated 04:15 PM EST

GVIP News

News
all
press releases
Wedbush, BTIG and Jefferies weighed in on ABVX on Tuesday after the company unveiled updated safety and efficacy data from an obefazimod study.
Stocktwits
Abivax said the findings strengthen the overall case for obefazimod and reinforce its favorable benefit-risk profile.
Stocktwits
Shares of ABVX closed down 44% on Tuesday, clocking its worst day ever, on reports of a number of non-melanoma skin cancers and other malignancies observed in its ulcerative colitis trial.
Stocktwits
The company dismissed the cancers observed in the trial as rare, occurring primarily in older patients, and largely unrelated to treatment.
Stocktwits

Advertisement|Remove ads.